Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429148 | 0.89 | HTT (0.40) | HTTCASP6AKR1B1LMNACYP2C19 | |
| SCHEMBL449885 | 0.88 | BACE1 (0.38) | BACE1HTTCASP6AKR1B1LMNA | |
| SCHEMBL445570 | 0.79 | BACE1 (0.37) | BACE1 | |
| SCHEMBL447119 | 0.78 | BACE1 (0.58) | BACE1HTTCASP6AKR1B1LMNA | |
| SCHEMBL444596 | 0.77 | CASP6 (0.39) | HTTCASP6AKR1B1LMNACYP2C19 | |
| SCHEMBL428953 | 0.76 | AKR1B1 (0.55) | AKR1B1 | |
| SCHEMBL429165 | 0.71 | BACE1 (0.43) | BACE1 | |
| SCHEMBL446794 | 0.68 | BACE1 (0.39) | BACE1HTTCASP6AKR1B1LMNA | |
| SCHEMBL449103 | 0.66 | AKR1B1 (0.50) | BACE1HTTCASP6AKR1B1LMNA | |
| SCHEMBL2551830 | 0.64 | AKR1B1 (0.38) | CASP6AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885HTT 13/4885CASP6 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.